ClinicalTrials.gg
CompletedNCT00191815Updated Nov 11, 2009Results posted

Combination Chemotherapy for Metastatic Breast Cancer

A Phase 2 interventional study of Gemcitabine and cisplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-11-11.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
43rd of 90
70 · median 68
Started
2002
with 8 others
Phase 2
65 of 95
none open now
Registered
22nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 43rd largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2002, is one of 65 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the objective tumor response of the first-line therapy combination of gemcitabine and cisplatin in patients with metastatic breast cancer

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You are female in the age of 18 to 75 years old.
  • You have been diagnosed with the breast cancer.
  • You have desire and an opportunity to visit your doctor in medical site, both during realization of the active treatment program, and within 24 months of medical follow up.
  • You must sign this form

Exclusion criteria

Exclusion Criteria:

  • You are pregnant or breastfeeding.
  • Your laboratory parameters fall outside the limits, admitted by requirements of the present clinical study.
  • You have been diagnosed with serious concomitant or acute infectious disease.
  • You have used experimental medications within the last month.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Gemcitabine + Cisplatin

    Drug: Gemcitabine · Drug: cisplatin

Interventions

  • Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).

  • Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using World Health Organization (WHO) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

    Time frame: baseline to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration. Data collected every 4 months.)

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: first documented complete or partial response to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)

  2. Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression.

    Time frame: first active treatment dose to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)

  3. Time to Treatment Failure

    Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment.

    Time frame: first active treatment dose to last contact for patients, death as a result of any cause, or early discontinuation of treatment (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)

  4. Survival Time

    Overall survival is the duration from enrollment to death due to any cause.

    Time frame: first active treatment dose to date of death due to any cause (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)

  5. Number of Participants With Maximum Common Toxicity Criteria-National Cancer Institute Toxicity (CTC-NCI) of Gemcitabine-Cisplatin Combination

    The CTC provides descriptive terminology for adverse event reporting. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death).

    Time frame: Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)

  6. Number of Participants With Hematology Maximum Common Toxicity Criteria - National Cancer Institute Grades

    Maximum CTC-NCI toxicity grade for hematology. Grades range from 0 (none) to 5 (death).

    Time frame: Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)

  7. Number of Deaths

    Time frame: Baseline through follow-up (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)

  8. Number of Participants With Adverse Events Leading to Discontinuation

    Time frame: Baseline through eight 21-day cycles

07

Results

Posted Aug 19, 2009

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine + Cisplatin
Started70
Treated67
Completed30
Not completed40
Withdrew: Adverse event2
Withdrew: Disease progression or relapse24
Withdrew: Death2
Withdrew: Protocol violation3
Withdrew: Physician decision2
Withdrew: Withdrawal by subject7

Outcome measures

PrimaryObjective Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using World Health Organization (WHO) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.

Time frame:
baseline to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration. Data collected every 4 months.)
Reported as:
Number · participants
Objective Tumor Response
participantsGemcitabine + Cisplatin
Complete Response7
Partial Response19
Stable Disease19
Progressive Disease5
Not Assessable4
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
first documented complete or partial response to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Reported as:
Median · weeks
Duration of Response
weeksGemcitabine + Cisplatin
Duration of Response32.7 (26.9 to 48.6)
SecondaryTime to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression.

Time frame:
first active treatment dose to measured progressive disease (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Reported as:
Median · weeks
Time to Progressive Disease
weeksGemcitabine + Cisplatin
Time to Progressive Disease33.9 (23.9 to 48.0)
SecondaryTime to Treatment Failure

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment.

Time frame:
first active treatment dose to last contact for patients, death as a result of any cause, or early discontinuation of treatment (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Reported as:
Median · weeks
Time to Treatment Failure
weeksGemcitabine + Cisplatin
Time to Treatment Failure26.2 (19.6 to 34.9)
SecondarySurvival Time

Overall survival is the duration from enrollment to death due to any cause.

Time frame:
first active treatment dose to date of death due to any cause (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Reported as:
Median · weeks
Survival Time
weeksGemcitabine + Cisplatin
Survival Time84.0 (58.6 to 119.3)
SecondaryNumber of Participants With Maximum Common Toxicity Criteria-National Cancer Institute Toxicity (CTC-NCI) of Gemcitabine-Cisplatin Combination

The CTC provides descriptive terminology for adverse event reporting. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death).

Time frame:
Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)
Reported as:
Number · participants
Number of Participants With Maximum Common Toxicity Criteria-National Cancer Institute Toxicity (CTC-NCI) of Gemcitabine-Cisplatin Combination
participantsGemcitabine + Cisplatin
Allergic reaction/hypersensivity - Grade 11
Allergic reaction/hypersensivity - Grade 21
Allergic reaction/hypersensivity - Grade 30
Allergic reaction/hypersensivity - Grade 40
Allergic rhinitis - Grade 11
Allergic rhinitis - Grade 20
Allergic rhinitis - Grade 30
Allergic rhinitis - Grade 40
Other auditory/hearing - Grade 10
Other auditory/hearing - Grade 20
Other auditory/hearing - Grade 31
Other auditory/hearing - Grade 40
Blood/Bone marrow - other - Grade 10
Blood/Bone marrow - other - Grade 20
Blood/Bone marrow - other - Grade 30
Blood/Bone marrow - other - Grade 41
Cardiac- ischemia/infarction - Grade 10
Cardiac- ischemia/infarction - Grade 20
Cardiac- ischemia/infarction - Grade 31
Cardiac- ischemia/infarction - Grade 40
Hypertension - Grade 10
Hypertension - Grade 21
Hypertension - Grade 30
Hypertension - Grade 40
Hypotension - Grade 10
Hypotension - Grade 20
Hypotension - Grade 30
Hypotension - Grade 41
Fatigue - Grade 16
Fatigue - Grade 21
Fatigue - Grade 30
Fatigue - Grade 40
Fever - Grade 10
Fever - Grade 21
Fever - Grade 30
Fever - Grade 40
Rigors, chills - Grade 11
Rigors, chills - Grade 20
Rigors, chills - Grade 30
Rigors, chills - Grade 40
Weight loss - Grade 11
Weight loss - Grade 21
Weight loss - Grade 30
Weight loss - Grade 40
Alopecia - Grade 11
Alopecia - Grade 23
Alopecia - Grade 30
Alopecia - Grade 40
Rash/desquamation - Grade 10
Rash/desquamation - Grade 20
Rash/desquamation - Grade 31
Rash/desquamation - Grade 40
Anorexia - Grade 14
Anorexia - Grade 20
Anorexia - Grade 30
Anorexia - Grade 40
Constipation - Grade 11
Constipation - Grade 20
Constipation - Grade 30
Constipation - Grade 40
Mucositis due to radiation - Grade 12
Mucositis due to radiation - Grade 20
Mucositis due to radiation - Grade 30
Mucositis due to radiation - Grade 40
Nausea - Grade 110
Nausea - Grade 28
Nausea - Grade 32
Nausea - Grade 40
Vomiting - Grade 14
Vomiting - Grade 27
Vomiting - Grade 31
Vomiting - Grade 40
SGPT (ALT) - Grade 10
SGPT (ALT) - Grade 21
SGPT (ALT) - Grade 30
SGPT (ALT) - Grade 40
Infection without neutropenia - Grade 11
Infection without neutropenia - Grade 20
Infection without neutropenia - Grade 30
Infection without neutropenia - Grade 40
Insomnia - Grade 10
Insomnia - Grade 20
Insomnia - Grade 31
Insomnia - Grade 40
Abdominal pain or cramping - Grade 11
Abdominal pain or cramping - Grade 21
Abdominal pain or cramping - Grade 30
Abdominal pain or cramping - Grade 40
Headache - Grade 10
Headache - Grade 20
Headache - Grade 31
Headache - Grade 40
Pain - Other - Grade 10
Pain - Other - Grade 20
Pain - Other - Grade 31
Pain - Other - Grade 40
Renal/Genitourinary - Other - Grade 11
Renal/Genitourinary - Other - Grade 20
Renal/Genitourinary - Other - Grade 31
Renal/Genitourinary - Other - Grade 40
SecondaryNumber of Participants With Hematology Maximum Common Toxicity Criteria - National Cancer Institute Grades

Maximum CTC-NCI toxicity grade for hematology. Grades range from 0 (none) to 5 (death).

Time frame:
Baseline up to 30 days after last dose of study drug (eight 21-day cycles of therapy)
Reported as:
Number · participants
Number of Participants With Hematology Maximum Common Toxicity Criteria - National Cancer Institute Grades
participantsGemcitabine + Cisplatin
Hemoglobin (g/L) - Grade 135
Hemoglobin (g/L) - Grade 220
Hemoglobin (g/L) - Grade 35
Hemoglobin (g/L) - Grade 41
Neutrophils (x10E9/L) - Grade 16
Neutrophils (x10E9/L) - Grade 225
Neutrophils (x10E9/L) - Grade 313
Neutrophils (x10E9/L) - Grade 410
Platelets (x10E9/L) - Grade 143
Platelets (x10E9/L) - Grade 22
Platelets (x10E9/L) - Grade 31
Platelets (x10E9/L) - Grade 40
White Blood Cells (x10E9/L) - Grade 116
White Blood Cells (x10E9/L) - Grade 227
White Blood Cells (x10E9/L) - Grade 318
White Blood Cells (x10E9/L) - Grade 43
SecondaryNumber of Deaths
Time frame:
Baseline through follow-up (eight 21-day cycles of therapy and follow-up period was 24 months starting from the date of the last drug administration.)
Reported as:
Number · participants
Number of Deaths
participantsGemcitabine + Cisplatin
Disease Progression35
Ventricular Fibrillation1
Circulatory Arrest1
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation
Time frame:
Baseline through eight 21-day cycles
Reported as:
Number · participants
Number of Participants With Adverse Events Leading to Discontinuation
participantsGemcitabine + Cisplatin
Patients with >=1 AE leading to discontinuation2
Pneumonia1
Toxic skin eruption1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine + Cisplatin———
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventGemcitabine + Cisplatin
Atrial fibrillationCardiac disorders1/67
Ventricular fibrillationCardiac disorders1/67
Gastrointestinal perforationGastrointestinal disorders1/67
PeriproctitisGastrointestinal disorders1/67
General physical health deteriorationGeneral disorders1/67
Escherichia sepsisInfections and infestations1/67
PneumoniaInfections and infestations1/67
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/67
Renal failure acuteRenal and urinary disorders1/67
PleurisyRespiratory, thoracic and mediastinal disorders1/67
Most frequent other events
Most frequent other events
EventGemcitabine + Cisplatin
NauseaGastrointestinal disorders23/67
NeutropeniaBlood and lymphatic system disorders16/67
AstheniaGeneral disorders14/67
VomitingGastrointestinal disorders12/67
HyperkalaemiaMetabolism and nutrition disorders9/67
Weight decreasedInvestigations7/67
HypocalcaemiaMetabolism and nutrition disorders6/67
HypercalcaemiaMetabolism and nutrition disorders5/67
CoughRespiratory, thoracic and mediastinal disorders5/67
AlopeciaSkin and subcutaneous tissue disorders4/67

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine + Cisplatin
Mean50.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine + Cisplatin
Female70
Male0
Region of Enrollment
Region of Enrollment(participants)Gemcitabine + Cisplatin
Russian Federation63
Germany7
Menopausal Status
Menopausal Status(participants)Gemcitabine + Cisplatin
Pre-menopausal16
Post-menopausal54
Pathological Diagnosis
Pathological Diagnosis(participants)Gemcitabine + Cisplatin
Ductal breast carcinoma44
Ductal and lobular breast carcinoma2
Lobular breast carcinoma5
Mucinous breast carcinoma1
Adenocystic breast carcinoma10
Papillary carcinoma1
Unknown7
Stage of Disease at Entry to the Study
Stage of Disease at Entry to the Study(participants)Gemcitabine + Cisplatin
Stage IIIb1
Stage IV69
Stage of Disease at Time of Diagnosis
Stage of Disease at Time of Diagnosis(participants)Gemcitabine + Cisplatin
Stage I3
Stage IIa13
Stage IIb22
Stage IIIa12
Stage IIIb15
Stage IV5
Time from Initial Diagnosis to Study Entry
Time from Initial Diagnosis to Study Entry(month)Gemcitabine + Cisplatin
Mean37.6 ± 39.7
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5PM Eastern time (UTC/ GMT - 5hours, EST), or speak with your personal physician
    Munich, 81377, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9AM to 5PM Eastern time (UTC/ GMT - 5hours, EST), or speak with your personal physician
    Moscow, 115478, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Oct 2002
CompletionActual
Oct 2007
Results first posted
Aug 19, 2009
Last update
Nov 11, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191815
First posted
Sep 19, 2005
Start date
Oct 2002
Completion
Oct 2007
Results posted
Aug 19, 2009
Last update
Nov 11, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST),
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion